Next generation diagnostics to personalize breast cancer treatment
Utilizing the Endocrine Activity Index®, Delphi Diagnostics is providing new information to help healthcare providers optimize treatment decisions
Our Technology
Current breast cancer diagnostic tests do not provide all the information necessary for optimal treatment decisions. The Endocrine Activity Index is an innovative diagnostic that provides new information that can help optimize treatment decisions and avoid non-beneficial treatments.
Endocrine Activity Index
The Endocrine Activity Index measures endocrine transcriptional activity in Stage II-III, HR+, HER2- breast cancer patients. Understanding endocrine activity levels can help determine which patients will benefit the most from a dose-intense chemotherapy regimen.
Endocrine Activity Index RR
The Endocrine Activity Index Recurrence Risk (EAI RR) combines the genomic measurement of endocrine activity with baseline tumor and patient risk factors to inform breast cancer prognosis. EAI RR has been shown to be a consistent prognostic indicator for long-term outcomes in Stage II-III breast cancer patients.
Latest News
New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy.
Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting
Our Mission
Breast Cancer affects over 2.3 million patients globally each year. Today, breast cancer diagnostic tests answer broad questions to direct treatment decisions. Delphi Diagnostics is on a mission to change this by providing innovative tests to give more specific information, optimize treatment decisions, maximize disease-free survival, and help patients avoid non-beneficial treatments.
1.Speers CW, et al., Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 Jan 17:JCO2201499. doi: 10.1200/JCO.22.01499
2.Metzger O.F., et al., Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. JCO 43, 1229-1239(2025). DOI:10.1200/JCO-24-01875